Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 10/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 6/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.54 |
| ▸ | CES2 | O00748 | 2/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23261082 | 1.00 | TP53 (0.60) | TP53POLBMAPTSMN1; SMN2CES2 | |
| SCHEMBL773574 | 0.83 | TP53 (0.44) | TP53POLBMAPTSMN1; SMN2CES2 | |
| SCHEMBL775966 | 0.82 | TP53 (0.45) | TP53POLBMAPTSMN1; SMN2CES2 | |
| SCHEMBL30764260 | 0.81 | TP53 (0.57) | TP53POLBMAPTSMN1; SMN2CES2 | |
| SCHEMBL23260990 | 0.81 | TP53 (0.57) | TP53POLBMAPTSMN1; SMN2CES2 | |
| SCHEMBL23261078 | 0.79 | TP53 (0.80) | TP53POLBMAPTSMN1; SMN2CES2 | |
| SCHEMBL23261020 | 0.79 | TP53 (0.80) | TP53POLBMAPTSMN1; SMN2CES2 | |
| SCHEMBL30764479 | 0.79 | TP53 (0.80) | TP53POLBMAPTSMN1; SMN2CES2 | |
| SCHEMBL30764422 | 0.79 | TP53 (0.80) | TP53POLBMAPTSMN1; SMN2CES2 | |
| SCHEMBL23261080 | 0.79 | TP53 (0.70) | TP53POLBMAPTSMN1; SMN2PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11884647-B2 | Compounds and methods for targeting pathogenic blood vessels | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-01-30 | — | — | US | claimed |
| US-12612385-B2 | Compounds and methods for targeting pathogenic blood vessels | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-04-28 | — | — | US | disclosed |
| US-20240270717-A1 | COMPOUNDS AND METHODS FOR TARGETING PATHOGENIC BLOOD VESSELS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-08-15 | — | — | US | disclosed |
| US-11884647-B2 | Compounds and methods for targeting pathogenic blood vessels | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240270717-A1 | COMPOUNDS AND METHODS FOR TARGETING PATHOGENIC BLOOD VESSELS | TEK, KDR, LIPG | TP53 1102/4885POLB 2962/4885MAPT 1444/4885 |
| US-11884647-B2 | Compounds and methods for targeting pathogenic blood vessels | TEK, KDR, LIPG | TP53 1187/4885POLB 3488/4885MAPT 1494/4885 |
| US-12612385-B2 | Compounds and methods for targeting pathogenic blood vessels | KDR, TEK, FLT4 | TP53 2196/4885POLB 2389/4885MAPT 2027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.